34
Participants
Start Date
August 4, 2017
Primary Completion Date
February 17, 2020
Study Completion Date
February 17, 2020
Birinapant
Birinapant intravenous (IV) on Days 1 and 8 of each 21-Day Cycle. The following escalating doses of birinapant to be studied: 5.6, 11, 17, and 22 mg/m2. In the expansion phase the assigned recommended phase two dose will be administered in all cohorts
Pembrolizumab
200 mg pembrolizumab IV on Day 1 of each 21-Day Cycle
Thomas Jefferson University Sidney Kimmel Cancer Center, Philadelphia
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore
Mid Florida Hematology and Oncology Center, Orange City
Mary Crowley Cancer Research, Dallas
MD Anderson Cancer Center, The University of Texas, Houston
Banner MD Anderson Cancer Center, Gilbert
Cedars-Sinai Medical Center, Los Angeles
UCLA Dept of Medicine-Hematology/Oncology, Santa Monica
Beth Israel Deaconess Medical Center, Boston
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Medivir
INDUSTRY